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Abstract .
Methotrexate may cause seizures, dementia, and leukoencephalopathy when given in toxic doses to children with leukemia or
solid tumors. Even in therapeutic doses, treatment with this drug is associated with an increased incidence of seizures in
children with leukemia. To study mechanisms of injury, juvenile rats were given multiple intraventricular injections of
methotrexate and the brains were analyzed for histopathology and biogenic amine metabolites of dopamine and serotonin.
Disruption of monoamine metabolism has been proposed as a cause of brain dysfunction from this chemotherapy. Multiple
injections (1 or 2 mg/kg) produced convulsions in an increasingly larger percentage of animals at higher cumulative doses,
and five doses produced the neuropathological changes seen in human leukoencephalopathy. A single dose reduced the
concentration of brain metabolites of dopamine, but not serotonin, six hours later. The effect was less pronounced after five
doses. This rodent model should be useful for studying the metabolic basis of methotrexate encephalopathy. (J Child Neurol
1986;1:351-357)
ethotrexate (Folex, Mexate), a folic acid an-
~ tagonist, is commonly administered in-
trathecally as an integral component of the prophylaxis
and treatment of acute lymphocytic leukemia and other
malignancies in children. When administered in high
doses alone or in combination with craniospinal irra-
diation, it may produce a variety of adverse central
nervous system reactions.’-’ Acute reactions to high
doses include seizures, myelopathy, and arachnoidi-
tis.7,s Dementia, learning disabilities, or more subtle
personality changes may also develop in children after
chronic treatment.9-14 An increased incidence of sei-
zures in children treated for leukemia may be associ-
ated with the size of the methotrexate dose.l5 Even in
asymptomatic children, brain atrophy, focal lucencies,
and intracranial calcifications are often seen on com-
puted tomographic (CT) scans. 16,17 Radiologic and
pathologic studies have demonstrated that the drug
has a propensity to injure white matter, producing a
typical, predominantly periventricular leukoencepha-
lopathy.18-23
The mechanisms causing methotrexate encepha-
lopathy remain obscure. Methotrexate’s most promi-
nent action is to bind competitively to the enzyme
dihydrofolate reductase, restricting the availability of
reduced folic acid and, thus, interfering with intracel-
lular methylation reactions.24 In rapidly dividing cancer
cells, the antimetabolite appears to act primarily by
limiting the availability of purine and pyrimidine pre-
cursors of DNA. In the brain, dihydrofolate reductase
may play an additional biochemical role in generation
of reduced biopterin, the rate limiting cofactor for
synthesis of the neurotransmitters dopamine and sero-
tonin. 25,26 Methotrexate may also inhibit the enzyme
dihydropteridine reductase, which is the primary syn-
thetic enzyme for biopterin. Disruption of the produc-
tion of biogenic amine neurotransmitters by limiting
the supply of cofactor has been suggested as a mech-
anism for methotrexate encephalopathy. 21
To examine its effects on biogenic amine metabo-
lism, we developed an animal model for methotrexate
encephalopathy in young rats by repeated administra-
tion of intraventricular doses. We found that metho-
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trexate produced a behavioral syndrome of seizures
and neuropathologic alterations resembling the histo-
pathology seen in severe encephalopathy in humans.
To examine the hypothesis that methotrexate alters
biogenic amine metabolism, we studied the stable acid
metabolites of dopamine and serotonin in the brain
using a specific and sensitive high-performance liquid
chromatographic technique.
Methods
Four-week-old male Sprague-Dawley rats (approxi-
mately 130 g) were housed in individual cages, fed ad
libitum, and weighed every three days. For each set of
experiments, litter-mate controls exposed to identical
conditions and injected with diluent alone were in-
cluded.
To deliver methotrexate into the cerebral ventric-
ular system, animals were anesthetized with either a
xylazine-ketamine mixture or an Equithesin mixture
(pentobarbital, chloral hydrate, magnesium sulfate,
ethanol, and propylene glycol). The scalp was incised
in the midline, and a 2-mm deep opening through the
skull was made with a 26-gauge needle. The hole was
placed 2 mm lateral to the sagittal suture and 2 mm
posterior to the coronal suture. Crystalline methotrex-
ate without preservatives was dissolved in Elliot’s B
solution. Intracerebroventricular injection of drug or
diluent was made to a depth of 4 mm from the skull
surface with a Hamilton microliter syringe. The land-
marks for injection were established by injecting cresyl
violet suspension into the brain and examining its
distribution in the ventricular system. Injection vol-
umes ranged from 5 to 15 ILL. After each injection, the
scalp incision was closed and the animal was observed
for the next hour.
Doses of methotrexate of 1 or 2 mg/kg were ad-
ministered either as single doses or up to a maximum
of five repeated doses given at three-day intervals. The
2 mg/kg dose was equivalent to approximately 15 mg/
M2 of rat body surface area (surface area = 0.02 to 0.04
M2).2’ For multiple doses, the same opening was used
repeatedly. For each experimental group, controls re-
ceived equal numbers and volumes of injection of
Elliott’s B solution alone.
To define histopathologic changes induced by
methotrexate, five animals were injected with five
doses of methotrexate 2 mg/kg. Two days after the last
dose, these animals and three controls were deeply
anesthetized with chloral hydrate and perfused
through the heart with 10% buffered formalin. The
brains were removed intact, immersion fixed in 10%
formalin/30% sucrose for 1 week, and frozen sections
(20 Jlm) were cut in the coronal plane. Sections were
stained either for Nissl substance, for myelin with
Luxol fast blue/cresyl violet, or with phosphotungstic
acid and hematotoxylin (PTAH) to visualize reactive
glia. The neuropathologic changes were examined in
two separate sets of animals.
Three groups of animals were used for neurochem-
ical analysis. The first group was anesthetized with the
Equithesin mixture and received either one dose of
methotrexate (2 mg/kg) or Elliot’s B solution. A second
group received five doses of the drug at three-day
intervals. Animals in the third group were anesthetized
with xylazine-ketamine and were given five doses of
methotrexate (2 mg/kg). All animals were sacrificed by
decapitation six hours after the last injection, and the
corpus striatum was dissected out and frozen rapidly
at -70°C. Two stable acid metabolites of dopamine,
homovanillic acid (HVA) and dihydroxyphenylacetic
acid (DOPAC) and the serotonin metabolite 5-hydrox-
yindoleacetic acid (5-HIAA) were measured concur-
rently using high performance liquid chromatographic
electrochemical detection (HPLC-EC).28 Extracts of the
corpus striatum (caudate and putamen) were prepared
by homogenizing tissue in 500 AL of 0.1 M perchloric
acid containing 0.1 % sodium metabisulfite. One
hundred fifty microliters of 1 M Tris, pH 8.6 was added
to this suspension to enhance precipitation of particu-
late matter. After centrifugation at 18,000 rpm for 15
minutes, aliquots of supernatant were injected directly
into the high performance liquid chromatographic sys-
tem. The system included a 5 Jl, C-18 reverse phase
column (Altex), and an electrochemical detector (BAS)
with a glassy carbon electrode set at 0.78 volts v Ag/
AgCl reference electrode. The mobile phase used was
10% methanol in water with 0.01 M sodium acetate,
0.0001 M EDTA, with pH adjusted to 3.7. Concentra-
tions of DOPAC, HVA, and 5-HIAA were calculated
by comparison of peak heights with those of external
standards, and values were expressed per mg of tissue.
Student’s t-test was used to compare metabolite levels
in methotrexate- and diluent-treated animals.
Results
Behavior
A single dose of 1 mg/kg of methotrexate had no
obvious behavioral effects on any of the animals after
recovery from anesthesia, but repetition of this dose or
the administration of 2 mg/kg doses was associated
with an increasing incidence of seizures and systemic
toxicity (see Figure 1). The animals were irritable,
jumped at a slight noise, were thinner than controls,
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FIGURE 1
Incidence of seizures in rats after intraventricular methotrex-
ate. Rats were given either 1 or 2 mg/kg doses of intracere-
broventricular methotrexate or diluent at three-day intervals.
They were lightly anesthetized with ketamine-xylazine before
injection and observed for one hour afterward. Manifesta-
tions of seizures included multifocal twitching, running,
clonic jerking or stiffening of body or tail. N at each point:
45 animals were examined after one injection; 30 after two,
20 after three, and 14 after four injections.
and were poorly groomed after they received repeated
doses. The methotrexate-treated animals also appeared
unsteady and tended to remain immobile much of the
time. Twenty percent of the animals had obvious be-
havioral seizures after the first dose (2 mg/kg), while
more than 50% seized after the fourth dose (see Figure
1). Seizure manifestations included multifocal asym-
metric myoclonic jerks, focal clonic face movements
and body or tail stiffening, and generalized convul-
sions. When seizures were noted, they became appar-
ent between 15 and 60 minutes after the injection of
the drug. Seizures began when the animals were
emerging from anesthesia and occurred with both types
of anesthetics. Overt seizures rarely occurred for more
than an hour. No controls had any behavioral mani-
festations of seizures.
Histopathology
The animals given five doses of 2 mg/kg methotrexate
over 2 weeks had severe histopathologic changes in
their brains. Foci of spongy vacuolization and gliosis
were found in widespread areas and were especially
severe in the corpus striatum, cortex, and periventric-
ular white matter. Examination of myelin with Luxol
fast blue (see Figure 2) showed extensive areas of
fragmentation and dissolution combined with reactive
gliosis. These changes were particularly obvious in
periventricular areas and were present in all the ani-
mals examined after the high-dose schedule. Although
controls had areas of focal inflammation near the
needle tracts, none had the other histopathologic
changes. The brains did not have obvious changes of
hydrocephalus. The disrupted myelin and vacuoliza-
tion, as well as the gliosis and loss of oligodendroglia,
closely resembled the changes reported in human
methotrexate-induced leukoencephalopathy. The
methotrexate-treated brains also contained areas of
focal neuronal necrosis in the dorsal hippocampus,
striatum, and cortex.
Neurochemical Analysis
The corpus striatum was analyzed because of its heavy
concentration of dopamine and serotonin terminals
and its proximity to the lateral ventricles. Table 1
includes the dopamine and serotonin metabolite levels
in corpus striatum after one dose or five doses of
methotrexate (dose = 2 mg/kg). A single injection of
methotrexate produced a 44% decline (p < 0.001) in
the brain concentration of DOPAC and a 30% fall (p
FIGURE 2
Histopathologic changes in myelin of corpus callosum of rats
treated with 2 mg/kg of methotrexate every 3 days for total
of 5 doses. Panels A (control) and B (methotrexate) show
disruption of periventricular myelin seen in treated animals.
Area at arrow in B is shown at higher power in panel D,
where decreased myelin staining, vacuolization (stars) can be
seen compared with panel C (control). In addition, in same
area there is relative paucity of oligodendroglial nuclei, and




Striatal Monoamine Metabolites After Intraventricular Methotrexate (2 mg/kg)-
Equithesin Anesthesia
Methotrexate-treated rats were given 5 doses of drug in artificial CSF every three days intracer-
ebroventricularly and control animals were given artificial CSF alone. Before injection, they
were anesthetized with Equithesin. Five hours after the last dose, the animals were sacrificed
and analyzed, as described in Methods. Values expressed as mean ± standard error of mean.
* 
p < 0.001, Student’s t-test.
< 0.001) in HVA six hours after administration, but
the 5-HIAA concentration did not change. Although
the single dose produced a change in neurotransmitter
metabolism, it produced no obvious behavioral evi-
dence of neurotoxicity, and a transient decline in
weight gain after this dose generally was corrected in
the next week (data not shown). In contrast, toxicity
was noted in the animals given five consecutive doses
over an approximately two-week period and these
animals had histopathologic changes of leukoen-
cephalopathy. Despite the severity of their neuropatho-
logic lesions, the animals given multiple injections had
no significant reductions in striatal levels of HVA or
DOPAC. There was an increase in the striatal content
of the serotonin metabolite 5-HIAA (see Table 1).
Seizures have been reported to elevate monoamine
metabolites in the striatum, and the anesthesia used
for the repeated intraventricular injections modified
the expression of seizures. The barbiturate-containing
anesthetic mixture Equithesin appeared to delay the
onset of seizures and reduced their severity. Therefore,
we also examined a large group of animals given
ketamine-xylazine anesthesia that did not contain bar-
biturates to determine whether this had any effect on
the monoamine metabolites. In this large group of
animals, there was a modest but significant fall in HVA
after five doses of methotrexate (see Table 2). The fall
in DOPAC (-16% ) was not statistically significant,
although it was identical to the change in HVA. In
contrast to the results from experiments done with the
Equithesin anesthesia mixture, 5-HIAA declined only
modestly. These results suggest that a single dose of
methotrexate lowered DOPAC and HVA, measures of
dopamine turnover, but that with chronic administra-
tion, methotrexate’s impact on dopamine metabolism
is attenuated.
Discussion
Injection of repeated doses of methotrexate into the
ventricular system of young rats produced seizures,
systemic toxicity, and histopathologic changes charac-
teristic of leukoencephalopathy in humans. These
changes have not been studied and reported previously
in a rodent model, and they provide additional evi-
dence that methotrexate itself, without radiation, has a
specific toxic effect on the brain. 
1
The induction of seizures confirms previous obser-
vations in humans and animals that methotrexate is an
epileptogenic agent. 7,15,29 The basis for methotrexate’s
TABLE 2
Striatal Monoamine Metabolites After Fifth Dose of Intraventricular Methotrexate
(2 mg/kg)
Methotrexate-treated rats were given 5 doses of drug in artificial CSF every three days and
control animals were given artificial CSF alone. Before injection, they were anesthetized with
ketamine-xylazine. Five hours after the fifth dose, the animals were sacrificed and the tissue
dissected rapidly for analysis, as described in Methods. Values are expressed as mean ± standard
error of mean.
* 
p < 0.01, Student’s t-test.
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convulsant effects is uncertain. Since methotrexate
contains a glutamate moiety within its structure, one
possible mechanism for this action is a direct excitotoxic
effect of this amino acid.29 Continued treatment was
associated with an increasing incidence of seizures after
later doses, suggesting that earlier brain injury occurred
that sensitized the animals to the convulsive effect.
Areas of focal neuronal necrosis noted in the hippo-
campus, striatum, and cortex may have been related to
repeated seizures. These changes may parallel the pa-
thology that underlies the increased incidence of sei-
zures in children treated with methotrexate.
The neuropathologic changes described in patients
with encephalopathy from methotrexate or methotrex-
ate combined with radiation include spongy vacuoli-
zation of brain parenchyma, demyelination, nonin-
flammatory necrosis of white matter, axonal swelling
and necrosis, destruction of oligodendroglia, reactive
gliosis, and calcification. 18-23,30,31 We observed most of
these changes in the methotrexate-treated rats. The
brains have not yet been examined with stains specific
for axonal changes. Calcification was not observed but
it may not have had time to form during these short
experimental periods. 30 Spongy degeneration of the
brain and necrosis and vacuolization of myelin were
quite striking in all the brains examined. The individual
doses (2 mg/kg) that cumulatively produced severe
clinical and neuropathologic charges are high, but
probably not far out of the upper range seen in clinical
practice. Based on an estimate of surface area for the
rats used in the experiments of 0.02-0.04 M2,27 the
single dose of 2 mg/kg body weight approximated 15
mg/m2. However, because of the direct administration
of drug into the lateral ventricle, the brain was exposed
to a much higher concentration than would occur after
typical lumbar intrathecal placement.32 Nevertheless
the temporally compressed, high-dose methotrexate
protocol that produced changes in the rats may repli-
cate drug exposure seen in certain clinical situations.
These levels may be reached in patients with disrupted
cerebrospinal fluid dynamics, those receiving direct
methotrexate administration into the ventricular sys-
tem, and patients who receive accidental over-
doses. 7,33,34
The results suggest that intracerebroventricular
administration of methotrexate to young rats may be
useful as a model for leukoencephalopathy to elucidate
mechanisms of toxicity. Although clinical methotrexate
toxicity involves prominent behavioral and cognitive
abnormalities and seizures, virtually no information is
available on the drug’s effect on neuronal metabolism
in the central nervous system.2’8’25 We focused on the
effects of methotrexate on the stable acid metabolites
of dopamine and serotonin because of the possible
biochemical link between their biosynthetic pathways
and biopterin cofactor. Biopterin is highly concentrated
in the brain in catecholamine nerve terminals in the
caudate and putamen that are relatively close to the
ventricular surface.35 Biopterin required for biosyn-
thesis of dopamine and protein is recycled by the
enzyme dihydropteridine reductase, which is present
in the brain.36 In vitro evidence from rat pineal glands
suggests that methotrexate can reduce the concentra-
tion of biopterin at clinically relevant concentrations
(10 ~mol) presumably by inhibiting dihydropteridine
reductase.37 Methotrexate inhibition of biopterin syn-
thesis by dihydrofolate reductase could also contribute
to alterations in biogenic amine metabolism, although
recent in vitro data suggest that this is a minor path-
way.38 If methotrexate disrupts neuronal metabolism
by inhibiting biopterin production, we hypothesized
that it should reduce the brain tissue levels of dopamine
and serotonin metabolites. Similar changes have been
observed in children with decreased BH4 secondary to
an inherited deficiency of dihydropteridine reduc-
tase. 39-41
A single injection of methotrexate significantly re-
duced the concentrations of DOPAC and HVA in
animals anesthetized with the barbiturate-containing
anesthesia, but this effect was attenuated after five
injections. Repetition of the neurochemical studies after
five doses of methotrexate in the nonbarbiturate an-
esthetized group demonstrated a small but significant
reduction in HVA, but not DOPAC, which is the
predominant intraneuronal dopamine metabolite in the
rat. Therefore, the data provide some support for the
contention that methotrexate may disrupt monoamine
metabolism. The similar trends in the results from a
large number of animals treated with two different
anesthetics suggest that the type of anesthetic played
little role. However, the modest change found in the
sickest animals and the absence of a direct dose-re-
sponse relationship make it unlikely that the effect on
neurotransmitter metabolism is causally related to the
prominent neuropathologic changes.
Although alterations in biogenic amines may have
little relationship to severe structural brain damage
produced by methotrexate, the early reductions suggest
that this mechanism could play a role in transient
behavioral changes that have been noted in certain
patients.8-11 Low cerebrospinal fluid levels of HVA and
5-HIAA have been measured in some children during
treatment with intrathecal methotrexate for leuke-
mia.42,43 Although some of these children had behav-
ioral symptoms (lassitude, headache, and anorexia), it
is difficult to establish a causal relationship between
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methotrexate toxicity, low neurotransmitter metabolite
levels, and transient encephalopathy. The changes
could result from reduced neurotransmitter turnover
or suppression of neurotransmitter catabolism.z6 How-
ever, methotrexate has not been reported to inhibit
catabolic enzymes such as monoamine oxidase. At-
tempts to study this issue in human cerebrospinal fluid
are difficult to interpret because methotrexate infusion
appears to elevate cerebrospinal fluid concentrations
of HVA and 5-HIAA, perhaps by blocking their egress
from the cerebrospinal fluid. In leukemic children
undergoing routine induction and intensification ther-
apy that includes intrathecal methotrexate, a gradual
rise in cerebrospinal fluid 5-HIAA and HVA evolves
during the 9-week period.43 Similarly, in rhesus mon-
keys, we found that relatively low doses of methotrex-
ate (0.05 mg/kg/day) markedly elevated cerebrospinal
fluid metabolites; however, higher, toxic doses sup-
pressed the metabolite concentrations to normal or low
levels.34 Since we did not observe any increase in brain
levels of these metabolites in rodents after high-dose
methotrexate, these studies taken together suggest that
methotrexate has distinct effects on monoamine me-
tabolism in the brain and cerebrospinal fluid compart-
ments.
Methotrexate is a potent neurotoxin with several
possible mechanisms of action. Disruption of neuro-
transmitter synthesis or metabolism could account for
transient encephalopathic features, but it is unlikely
that this action leads to permanent neuronal damage.
Leukoencephalopathy, a more serious progressive ill-
ness, is produced by several distinct therapies including
methotrexate radiation and other chemotherapeutic
agents such as cytosine arabinoside.4-6,43,44 One effect
shared by these treatments is their ability to inhibit
protein synthesis.45 Inhibition of active protein turn-
over in myelin might be expected to disrupt critical
structural components and oligodendroglia. The ani-
mal model may be used to examine this and other
potential neurotoxic mechanisms.
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